Skip to main content

Advertisement

SpringerLink
Log in

Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor α release in vitro of activated human monocytic leukemia cells

  • Laboratory Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

GLC756, a putative antiglaucoma drug with dopamine D2 agonist and D1 antagonist properties, significantly decreases tumor necrosis factor α (TNF-α) levels in lipopolysaccharide (LPS)-induced rats. The present study describes the effects of GLC756 on cellular adenosine 3′, 5′-cyclic monophosphate (cAMP) in relation to TNF-α production on LPS-stimulated human acute monocytic leukemia cells.

Methods

A human peripheral blood acute monocytic leukemia cell line (THP-1) was activated via LPS. THP-1 cells were incubated with GLC756 or betamethasone (positive control) at concentrations of 1, 10, and 30 μM. The TNF-α concentration in supernatant and cAMP levels in cellular extract were measured by enzyme-linked immunosorbent assay 0,1, 2.5, 4.5, 7, and 24 h post-activation.

Results

Compared with LPS controls, both GLC756 at 30 μM and betamethasone at ≥1 μM had a significant inhibitory effect on TNF-α release from THP-1 cells 2.5 to 24 h post-activation. Parallel to the TNF-α decrease, GLC756 induced significant increases of cellular cAMP 2.5 and 7 h post-activation. Betamethasone had no effect on the cellular cAMP level.

Conclusion

Intracellular signaling pathway leading to inhibition of the production of the proinflammatory cytokine TNF-α after GLC756 treatment might be mediated through the second messenger cAMP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pruente C, Flammer J. The novel dopamine D1 antagonist and D2 agonist, SDZ GLC 756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma. Ophthalmology 1995;102:1291–1297.

    Article  Google Scholar 

  2. Prünte C, Flammer J, Markstein R, Rudin M. Quantification of optic nerve blood flow using MR-imaging. Invest Ophthalmol Vis Sci 1995;36:247–251.

    PubMed  Google Scholar 

  3. Chiou GC, Chen YJ. Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow. J Ocul Pharmacol 1992;8:285–294.

    Article  CAS  PubMed  Google Scholar 

  4. Markstein R, Gull P, Rudeberg C, et al. SDZ GLC 756, a novel o ctahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm 1996;103:17–30.

    Article  CAS  PubMed  Google Scholar 

  5. Prunte C, Nuttli I, Markstein R. Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits. Jpn J Ophthalmol 1996;40:167–173.

    CAS  PubMed  Google Scholar 

  6. Längle UW, Trendelenburg AU, Markstein R, et al. GLC756 decreases TNF-α via an alpha2 and beta2 adrenoceptor related mechanism. Exp Eye Res 2006;83:1246–1251.

    Article  Google Scholar 

  7. Laengle UW, Markstein R, Schneider V, Roman D. Effects of antiglaucoma drugs GLC756, a novel dopamine D2 agonist and D1 antagonist, and timolol on endotoxin-induced TNF-alpha release in serum of rats. Eur J Ophthalmol 2006;16:401–406.

    Article  CAS  PubMed  Google Scholar 

  8. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci 1997;2:12–16.

    Google Scholar 

  9. Durum SL, Oppenheim JJ. In: Paul WE, editor. Fundamental immunology. New York: Ravens Press; 1989. p. 639–661.

    Google Scholar 

  10. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 2002;169:3801–3810.

    Article  CAS  PubMed  Google Scholar 

  11. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990;55:157–170.

    Article  CAS  PubMed  Google Scholar 

  12. Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999;36:275–328.

    Article  CAS  PubMed  Google Scholar 

  13. Juilfs DM, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 1999;135:67–104.

    Article  CAS  PubMed  Google Scholar 

  14. Simonds WF. G protein regulation of adenylate cyclase. Trends Pharmacol Sci 1999;20:66–73.

    Article  CAS  PubMed  Google Scholar 

  15. Meisel C, Vogt K, Platzer C, et al. Differential regulation of monocytic tumour necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 1996;26:1580–1586.

    Article  CAS  PubMed  Google Scholar 

  16. Kambayashi T, Jacob CO, Zhou D, et al. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNFα and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995;155:4909–4916.

    CAS  PubMed  Google Scholar 

  17. Foey, AD, Field S, Ahmed S, et al. Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 2003;5:317–328.

    Article  Google Scholar 

  18. Pradervand S, Maurya MR, Subramaniam S. Identification of signaling components required for the prediction of cytokine release in RAW 264.7 macrophages. Genome Biol 2006;7:R11.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Xu B, Makris A, Thornton C, Hennessy A. Glucocorticoids inhibit placental cytokines from cultured normal and pre-eclamptic placental explants. Placenta 2005;26:654–660.

    Article  CAS  PubMed  Google Scholar 

  20. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology 1989;96:327–335.

    Article  CAS  PubMed  Google Scholar 

  21. Ariturk N, Oge I, Baris S, et al. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int Ophthalmol 1997;20:57–62.

    Article  CAS  Google Scholar 

  22. Broadway DC, Grierson I., O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437–1445.

    Article  CAS  PubMed  Google Scholar 

  23. Shivachar AC, Eikenburg DC. Differential effects of epinephrine and norepinephrine on cAMP response and Gi3alpha protein expression in cultured sympathetic neurons. J Pharmcol Exp Ther 1999;291:258–264.

    CAS  Google Scholar 

  24. Foey AD, Field S, Ahmed S, et al. Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 2003;5:317–328.

    Article  Google Scholar 

  25. Szelényi J, Kiss JP, Puskás É, et al. Opposite role of α2- and β-adrenoceptors in the modulation of interleukin-10 production in endotoxaemic mice. Neuroreport 2000;11:3565–3568.

    Article  PubMed  Google Scholar 

  26. Fuziwara S, Suzuki A, Inoue K, Denda M. Dopamine D2-like receptor agonists accelerate barrier repair and inhibit the epidermal hyperplasia induced by barrier disruption. J Invest Dermatol 2005;125:783–789.

    Article  CAS  PubMed  Google Scholar 

  27. Sasaki T, Kotera J, Omori K. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 2004;89:474–483.

    Article  CAS  PubMed  Google Scholar 

  28. McKenna F, McLaughlin PJ, Lewis BJ, et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002;132:34–40.

    Article  CAS  PubMed  Google Scholar 

  29. Dürk T, Panther E, Müller T, et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int Immunol 2005;17:599–606.

    Article  PubMed  Google Scholar 

  30. Ye RD. β-Adrenergic agonists regulate NF-KB activation through multiple mechanisms. Am J Physiol Lung Cell Mol Physiol 2000;279:615–617.

    Article  Google Scholar 

  31. Taffet, SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989;120:291–300.

    Article  CAS  PubMed  Google Scholar 

  32. Viherluoto J, Palkama T, Silvennoinen O, Hurme M. Cyclic adenosine monophosphate decreases the secretion, but not the cell-associated levels, of interleukin-1β in lipopolysaccharideactivated human monocytes. Scand J Immunol 1991;34:121–125.

    Article  CAS  PubMed  Google Scholar 

  33. Spengler RN, Spengler ML, Lincoln P, Remick DG, et al. Dynamics of dibutyryl cyclic AMP- and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression. Infect Immun 1989;57:2837–2841.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Talmadge J, Scott R, Castelli P, et al. Molecular pharmacology of the β-adrenergic receptor on THP-1 cells. Int J Immunopharmacol 1993;15:219–228.

    Article  CAS  PubMed  Google Scholar 

  35. Zhang LM, Castresana MR, Shaker IJ, et al. Increased intracellular cyclic adenosine 3′, 5′-monophosphate inhibits release of tumor necrosis factor-alpha from human vascular tissue and cultured smooth muscle cells. Crit Care Med 1997;25:855–861.

    Google Scholar 

  36. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor B in inflammatory bowel disease. Gut 1998;42:477–484.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Toxicology & Pathology, Novartis Pharma AG, Basel, Switzerland

    Ulrich W. Laengle, Rudolf Markstein, Cecile Cazaubon & Danielle Roman

  2. Department of Toxicology & Pathology, Novartis Pharma AG, WKL-126.1.16, Klybeckerstr. 141, CH-4057, Basel, Switzerland

    Ulrich W. Laengle

Authors
  1. Ulrich W. Laengle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rudolf Markstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cecile Cazaubon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Danielle Roman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich W. Laengle.

About this article

Cite this article

Laengle, U.W., Markstein, R., Cazaubon, C. et al. Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor α release in vitro of activated human monocytic leukemia cells. Jpn J Ophthalmol 53, 159–163 (2009). https://doi.org/10.1007/s10384-008-0625-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-008-0625-8

Key Words

Search

Navigation